Home Healthcare Biopharmaceuticals and Biomedicine Market is Thriving Globally with Top Leading Key Players Novartis AG, Johnson & Johnson, Pfizer, Inc.
Biopharmaceuticals and Biomedicine Market is Thriving Globally with Top Leading Key Players Novartis AG, Johnson & Johnson, Pfizer, Inc.

Biopharmaceuticals and Biomedicine Market is Thriving Globally with Top Leading Key Players Novartis AG, Johnson & Johnson, Pfizer, Inc.

Biopharmaceuticals are drugs that are partially or fully manufactured, or extracted from biological sources. Biopharmaceuticals contain variety of products such as monoclonal antibodies, vaccines, recombinant human insulin, human growth hormone, erythropoietin, interferon, colony stimulating factor, and blood factors. Currently, biopharmaceuticals accounts for over one-fifth of pharmaceutical market, and this percentage share of biopharmaceutical is expected to increase, owing to its advantage compared to totally synthesize pharmaceutical drugs. Fewer side effects, high effectiveness and potent action, and ability to cure the disease rather than treat are some of the major advantages of these drugs.

 

Get Sample Copy At: https://www.coherentmarketinsights.com/insight/request-sample/18

 

Continuous launch, approvals, and robust pipeline of biopharmaceutical products is expected to drive growth of the market

 

In the recent past, regulatory bodies in key regions such as U.S. and Europe have approved a number of biopharmaceutical products, which have been subsequently launched in the market. For instance in 2017, Johnson & Johnson received U.S. FDA approval for its new immunology product—Tremfya (Guselkumab)—used for the treatment of moderate to severe plaque psoriasis. In 2017, Sanofi S.A. received U.S. FDA approval for its new Admelog, a rapid-acting insulin, indicated for the management of blood sugar levels at mealtime. In 2017, U.S. FDA approved GlaxoSmithKline Plc.’s New Shingrix, a shingles vaccine. FDA approved this vaccine to be used by people aged 50 years and above as an immunization against the painful condition caused by latent varicella infection. In 2017, Spark Therapeutics, Inc. received FDA approval for its LUXTURNA (voretigene neparvovec-rzyl). LUXTURNA is first gene therapy and pharmacologic treatment for an inherited retinal disease (IRD), and the first approved adeno-associated virus (AAV) vector gene therapy in the U.S. In 2017, HumanZyme Inc. launched its new HumanKine Interferon beta (IFN beta) expressed from HEK293 cells. IFN beta is an interferon of type I family, which activates Th1-type innate immune responses against viral and bacterial infection. In 2016, Novo Nordisk A/S launched its new next-generation once-daily basal insulin Tresiba (insulin degludec) in the U.S. market and in 2017, Nordisk A/S received China Food and Drug Administration (CFDA) approval to market its Tresiba (insulin degludec) in China. Such frequent launches and approvals of novel products is expected to drive growth of the market in the near future.

 

Increasing strategic acquisitions and collaboration by key players is expected to drive market growth in the near future

 

Players in the market are focusing on strategic collaborations, in order to increase their product offerings. In February 2018, LGC Limited— U.K.-based Company acquired Lucigen Corporation, a U.S.-based developer, and manufacturer of molecular biology enzymes, reagents and kits. Through this strategic acquisition, LGC Limited expanded its portfolio with the Lucigen’s extensive portfolio of NGS kits, enzymes, competent cells, and cloning systems. In February 2018, Servier Laboratories and ImmunoQure AG entered into a strategic collaboration for development of a therapeutic autoantibody neutralizing interferon- a. In March 2018, Wuxi Biologics Co. Ltd. collaborated with Adagene Inc., for the discovery and development of novel antibody therapeutics. In 2017, Omicia, Inc., acquired a bioinformatics startup Spiral Genetics at an undisclosed amount. Through this acquisition of Spiral’s advanced tools, Omicia, Inc., expanded its bioinformatics tools portfolio and strengthened its position in the global market.

 

Market Dynamics

 

Launches and approvals of novel biopharmaceutical and biomedicine products is expected to drastically drive growth of global biopharmaceutical and biomedicine market in the near future. For instance, in 2016, Sanofi S.A. received U.S. FDA approval for its Adlyxin ((lixisenatide) injection. Adlyxin is indicated to improve blood sugar levels among adults suffering from type 2 diabetes. In 2016, Johnson & Johnson received U.S. FDA approval for its Stelara (Ustekinumab), indicated for the treatment of adults suffering from moderately to severely active crohn’s disease. In 2016, CSL Behring received U.S. FDA approval for its IDELVION, Coagulation Factor IX (Recombinant), Albumin Fusion Protein. IDELVION is indicated for the treatment of Hemophilia B among children and adults. In 2017, Nanostring Technologies, Inc. launched nCounter platform advances as well as new panels expanding the company’s presence in immuno-oncology and 3D biology research. In 2015, Celltrion Healthcare Co., Ltd. launched its Remsima (infliximab), a biosimilar monoclonal antibody (mAb) in Austria, Belgium, Denmark, France, Germany, Greece, Italy, Luxembourg, the Netherlands, Spain, Sweden, and the UK. Furthermore, increasing collaborations and acquisitions by major key players in market is also expected to create lucrative environment for growth of market.

 

Request For Customization of Research Report @ https://www.coherentmarketinsights.com/insight/request-customization/18

 

Key players operating in the global biopharmaceutical and biomedicine market include Amgen Inc., F. Hoffmann-La Roche AG, Novartis AG, Johnson & Johnson, Pfizer, Inc., Sanofi S.A., Eli Lilly and Company, AbbVie Inc., Novo Nordisk A/S, Bristol - Myers Squibb, NanoString Technologies, Inc., Qiagen N.V., Celgene Corporation, and Affimed N.V.

 

About Coherent Market Insights

 

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.


YOU MAY ALSO LIKE